Clinical Trial

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-31; most recent amendment 2025-12-28.
Status change: Not Yet Recruiting → Recruiting 2025-12-28
Trial Details
NCT Number NCT07110064
Lead Sponsor Du Juan
Conditions Advance Pancreatic Cancer
Enrollment 80 participants
Start Date 2025-09-03
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-02